BeOne Medicines (BEIGF) Equity Average (2016 - 2026)

BeOne Medicines (BEIGF) has 11 years of Equity Average data on file, last reported at $4.6 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $4.6 billion, up 33.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 33.52% YoY), and the FY2025 annual result was $3.8 billion, up 11.99% from the prior year.
• Equity Average advanced to $4.6 billion in Q1 2026 per BEIGF's latest filing, from $4.2 billion in the prior quarter.
• Over five years, Equity Average peaked at $6.0 billion in Q1 2022 and troughed at $3.4 billion in Q2 2024.
• A 5-year average of $4.1 billion and a median of $3.9 billion in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2023: Equity Average surged 51.24% in 2022, then slipped 28.27% in 2023.
• A 5-year view of Equity Average shows it stood at $4.5 billion in 2022, then fell by 19.23% to $3.7 billion in 2023, then fell by 7.29% to $3.4 billion in 2024, then climbed by 25.45% to $4.2 billion in 2025, then advanced by 7.43% to $4.6 billion in 2026.
• Business Quant data shows BEIGF's Equity Average at $4.6 billion in Q1 2026, $4.2 billion in Q4 2025, and $3.9 billion in Q3 2025.